country

Change Language

EN - English
FR - Français
DE - Deutsch
ES - Español
JA - 日本語
KO - 한국어

Country or Region:

United States

Product Name	Size / Unit Price	Qty

Total: USD 0.00 Checkout

Art. -Nr.: HY-123013

Copy Link Print Information

Y 9000

Y 9000 is an orally active antiallergic and anti-inflammatory compound. Y 9000 targets mast cells, inhibits the release of allergic mediators, stimulates the adrenal glands, exhibits glucocorticoid-like activity, and reduces adrenal ascorbic acid content. Y 9000 inhibits IgE-mediated and IgG-mediated allergic reactions as well as active systemic anaphylaxis in mice. Y 9000 inhibits allergic wheezing in passively sensitized guinea pigs and protects against active systemic anaphylactic shock in mice. Y 9000 inhibits non-immune responses in rats, including dextran-induced histamine release, anaphylactoid reactions and paw swelling. Y 9000 can be used in the research of allergic diseases (asthma, allergic rhinitis, urticaria, etc.).

Nur für Forschungszwecke. Wir verkaufen nicht an Patienten.

CAS. Nr.: 53944-40-4
Formel: C₁₄H₉NO₃
Molecular Weight:239.23

Speicherung:

Please store the product under the recommended conditions in the Certificate of Analysis.

Data Sheet (277 KB)

Y 9000 Chemical Structure

CAS. Nr.: 53944-40-4

Größe

Preis

Verfügbarkeit

Menge

Amount: USD 0.00

* Bitte wählen Sie Menge, bevor Sie Artikel hinzufügen.

Top Publications Citing

Use of MCE Products

Fluorescent Dye

Strong Fluorescence Signal / Multi-Disciplinary Applications / High Fluorescence Specificity

Biologische Aktivität
- Beschreibung
- In Vivo
Chemical Information
Reinheit & Dokumentation
Verweise
Calculators
Help & FAQs
Classifications
Bioz

Biologische Aktivität

Beschreibung

In Vivo

Y 9000 (5-50 mg/kg; p.o.; single dose 1 hour pre-antigen; 0.5-50 mg/kg; i.p.; single dose 30 minutes pre-antigen) inhibits IgE-mediated 48-hour homologous PCA in rats in a dose-dependent manner, with an oral ED₅₀ of 11 mg/kg for egg albumin-induced PCA and intraperitoneal ED₅₀ of 2.7 mg/kg^[1].
Y 9000 (50-250 mg/kg; p.o.; single dose 1 hour pre-antigen; 5-100 mg/kg; i.p.; single dose 30 minutes pre-antigen; 25-100 mg/kg; p.o.; single dose 1 hour pre-antigen in adrenalectomized rats) inhibits IgG-mediated 4-hour heterologous PCA in intact rats in a dose-dependent manner, with an oral ED₅₀ of 75 mg/kg and intraperitoneal ED₅₀ of 14 mg/kg, and this inhibitory effect is reduced in adrenalectomized rats^[1].
Y 9000 (5-25 mg/kg; i.p.; single dose 30 minutes pre-antigen; 100 mg/kg; p.o.; single dose 2 hours pre-antigen) inhibits IgE-mediated active anaphylactic bronchoconstriction in sensitized rats in a dose-dependent manner via intraperitoneal and oral routes^[1].
Y 9000 (25-100 mg/kg; i.p.; single dose 30 minutes pre-aerosol challenge) inhibits IgG-mediated anaphylactic asthma in passively sensitized guinea pigs via intraperitoneal administration, with an ED₅₀ of 50 mg/kg^[1].
Y 9000 (100-500 mg/kg; p.o.; single dose 1 hour pre-antigen; 10-100 mg/kg; i.p.; single dose 30 minutes pre-antigen) dose-dependently protects against active systemic anaphylaxis in sensitized mice, with an oral ED₅₀ of ~250 mg/kg and intraperitoneal ED₅₀ of 50 mg/kg^[1].
Y 9000 (2.5-25 mg/kg; p.o.; single dose 1 hour pre-induction; 0.5-10 mg/kg; i.p.; single dose 30 minutes pre-induction) inhibits egg albumin-induced anaphylactoid reactions in rats in a dose-dependent manner via oral and intraperitoneal routes, with an oral ED₅₀ of 4 mg/kg and intraperitoneal ED₅₀ of 1 mg/kg^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:

Wistar rats (male, 180g body weight; male, 200g body weight; allergic reaction model via 48-hour homologous passive cutaneous anaphylaxis induced by anti-egg albumin rat serum or anti-dinitrophenol-ascaris rat serum)^[1]
Dosage:

5-50 mg/kg (p.o.); 0.5-50 mg/kg (i.p.)
Administration:

p.o.; single dose 1 hour pre-antigen; i.p.; single dose 30 minutes pre-antigen
Result:

Suppressed egg albumin-triggered PCA dose-dependently via oral and intraperitoneal routes, with oral ED₅₀ of 11 mg/kg and intraperitoneal ED₅₀ of 2.7 mg/kg.
Suppressed DNP-As-induced PCA orally in a serum dilution-dependent fashion, with ED₅₀ values of 30 mg/kg (1:30), 11 mg/kg (1:50) and ~4 mg/kg (1:100).

Animal Model:

Wistar rats (male, 180g body weight; adrenalectomized male, 180g body weight, 5 days post-surgery; allergic reaction model via 4-hour heterologous passive cutaneous anaphylaxis induced by anti-egg albumin rabbit serum)^[1]
Dosage:

50-250 mg/kg (p.o. intact rats); 5-100 mg/kg (i.p. intact rats); 25-100 mg/kg (p.o. adrenalectomized rats)
Administration:

p.o.; single dose 1 hour pre-antigen; i.p.; single dose 30 minutes pre-antigen
Result:

Suppressed IgG-dependent 4 hr heterologous PCA in normal rats dose-dependently, with oral ED₅₀ = 75 mg/kg and intraperitoneal ED₅₀ = 14 mg/kg.
Suppressed IgG-dependent 4 hr heterologous PCA by 26% and 61% at oral 25 mg/kg and 100 mg/kg in adrenalectomized rats.

Animal Model:

Wistar rats (female, 200g body weight; allergic asthma model via active anaphylactic bronchoconstriction induced by egg albumin and Bordetella pertussis vaccine sensitization)^[1]
Dosage:

5-25 mg/kg (i.p.); 100 mg/kg (p.o.)
Administration:

i.p.; single dose 30 minutes pre-antigen; p.o.; single dose 2 hours pre-antigen
Result:

Suppressed antigen-triggered anaphylactic bronchoconstriction dose-dependently via intraperitoneal injection and matched the potency of disodium cromoglycate; oral 100 mg/kg also exerted prominent suppressive effects.

Animal Model:

Guinea pigs (male, 300-400g body weight; allergic asthma model via anaphylactic asthma induced by passive sensitization with anti-egg albumin rabbit serum and egg albumin aerosol challenge)^[1]
Dosage:

25-100 mg/kg
Administration:

i.p.; single dose 30 minutes pre-aerosol challenge
Result:

Protected 0/10, 5/10, 6/10 animals from anaphylactic asthma at intraperitoneal doses of 25 mg/kg, 50 mg/kg, 100 mg/kg respectively, with an ED₅₀ of 50 mg/kg.

Animal Model:

ICR mice (female, 20-25g body weight; allergic reaction model via active systemic anaphylaxis induced by egg albumin and Bordetella pertussis vaccine sensitization)^[1]
Dosage:

100-500 mg/kg (p.o.); 10-100 mg/kg (i.p.)
Administration:

p.o.; single dose 1 hour pre-antigen; i.p.; single dose 30 minutes pre-antigen
Result:

Suppressed lethal active systemic anaphylaxis dose-dependently.

Animal Model:

Wistar rats (male, 180-200g body weight; anaphylactoid reaction model via egg albumin-induced anaphylactoid reaction)^[1]
Dosage:

2.5-25 mg/kg (p.o.); 0.5-10 mg/kg (i.p.)
Administration:

p.o.; single dose 1 hour pre-induction; i.p.; single dose 30 minutes pre-induction
Result:

Suppressed egg albumin-evoked anaphylactoid responses dose-dependently, with oral ED₅₀ of 4 mg/kg and intraperitoneal ED₅₀ of 1 mg/kg; intraperitoneal potency was approximately 3.4-fold higher than disodium cromoglycate.

Chemical Information

CAS. Nr. 53944-40-4
Molecular Weight 239.23
Formel C₁₄H₉NO₃
SMILES

O=C1C2=CC(C(C)=O)=CC=C2OC3=NC=CC=C31
Versand

Room temperature in continental US; may vary elsewhere.
Speicherung

Please store the product under the recommended conditions in the Certificate of Analysis.

Reinheit & Dokumentation

Select Batch:

Reinheit: 99.98%

Assay: 99.98%

ee.: 99.98%

Data Sheet (277 KB)
COA (2659 KB)
Elemental Analysis Report (2659 KB)
HNMR (2659 KB)
CNMR (2659 KB)
RP-HPLC (2659 KB)
NP-HPLC (2659 KB)
MS (2659 KB)
LCMS (2659 KB)
IR (2659 KB)
GC (2659 KB)
OR (2659 KB)
SDS-PAGE (2659 KB)
SEC-HPLC (2659 KB)
Other Report (2659 KB)
Handling Instructions (2659 KB)

Verweise

[1]. Maruyama Y, et al. [Anti-allergic activity of 7-acetyl-5-oxo-5H-[1] benzopyrano (2,3-b] pyridine (Y-9000) (author's transl)]. Nihon Yakurigaku Zasshi. 1978 Mar;74(2):179-91.

Calculators

Molaritätsrechner

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass Mass

Konzentration Konzentration

Volumen Volumen

Molecular Weight Molecular Weight

Verdünnungsrechner

Konzentration _{(Stammlösung)} × Volumen _{(Stammlösung)} = Konzentration _{(Ziellösung)} × Volumen _{(Ziellösung)}

Konzentration _{(Stammlösung)} Konzentration _{(Stammlösung)}

Volumen _{(Stammlösung)} Volumen _{(Stammlösung)}

Konzentration _{(Ziellösung)} Konzentration _{(Ziellösung)}

Volumen _{(Ziellösung)} Volumen _{(Ziellösung)}

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

Keywords

MOQ

Minimum order quantity

100 mg

Angebot einholen Auf Lager

Other size

Angebot einholen